ETF Holdings Breakdown of STOK

STOK institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	23,021	USD 569,309
2025-09-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,706	USD 165,839
2025-09-29	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	66,436	USD 1,642,962
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	31,721	USD 784,460 2.4%
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	31,721	USD 784,460
Total =		159,605	USD 3,947,030

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with STOK

Notable Wednesday Option Activity: AAPL, STOK, Z

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Apple Inc (Symbol: AAPL), where a total volume of 543,181 contracts has been traded thus far today, a contract volume which is representative of approximately 54 - 2025-09-17 16:17:22

Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $25.57

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among […] - 2025-08-22 03:12:53

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Better-Than-Expected Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s share price gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $13.53, but opened at $14.89. Stoke Therapeutics shares last traded at $15.14, with a volume of 236,029 shares changing hands. The company reported ($0.40) […] - 2025-08-15 02:34:48

40,181 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) during the 1st quarter, HoldingsChannel reports. The fund purchased 40,181 shares of the company’s stock, valued at approximately $267,000. Other large investors have also recently bought and sold shares of the company. RTW Investments LP raised its position in Stoke […] - 2025-08-12 04:30:53

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $25.80

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has received an average recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price […] - 2025-07-28 02:30:54

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up – Here’s What Happened

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $12.35, but opened at $12.93. Stoke Therapeutics shares last traded at $12.75, with a volume of 96,492 shares traded. Wall Street Analyst Weigh In A number of research analysts have recently weighed […] - 2025-07-20 05:22:59

Alps Advisors Inc. Sells 2,940 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Alps Advisors Inc. decreased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 6.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,890 shares of the company’s stock after selling 2,940 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-18 05:21:01

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average […] - 2025-06-30 02:34:50

Assenagon Asset Management S.A. Cuts Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Assenagon Asset Management S.A. lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 29.0% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 959,603 shares of the company’s stock after selling 391,322 shares during the period. Assenagon Asset Management S.A.’s holdings in Stoke Therapeutics were worth $6,381,000 as of […] - 2025-06-15 05:44:52

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets decreased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 94.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,422 shares of the company’s stock after selling 71,732 shares during the quarter. BNP Paribas Financial […] - 2025-06-04 05:14:48

Legal & General Group Plc Has $390,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Legal & General Group Plc trimmed its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,347 shares of the company’s stock after selling 2,139 shares during the quarter. Legal & General […] - 2025-05-01 04:42:53

Renaissance Technologies LLC Buys Shares of 129,043 Stoke Therapeutics, Inc. (NASDAQ:STOK)

Renaissance Technologies LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 129,043 shares of the company’s stock, valued at approximately $1,423,000. Other large investors have […] - 2025-04-29 04:58:53

Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 237.42% from […] - 2025-04-11 04:46:50

HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC […] - 2025-03-21 04:25:10

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 166.34% from the stock’s […] - 2025-03-20 04:44:48

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have earned an average rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy […] - 2025-02-28 04:26:56

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Target Price from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-03 04:24:54

Back to Listing

Disclaimer